** CVS Health CVS.N raised its full-year profit forecast on Thursday after beating Wall Street's quarterly earning estimates as tight oversight of higher medical costs improved performance of its Aetna health insurance business
** Rivals including UnitedHealth UNH.N, Elevance ELV.N and Centene CNC.N have warned of higher-than-expected medical costs in the second-quarter.
** 20 out of 29 analysts rate stock as buy or higher, 9 hold; Median PT is $80 - LSEG
CVS HEALTH ON THE RIGHT TRACK
** Evercore ISI ("outperform," PT: $85) says CVS is moving with clearer operational focus and sharper discipline under new management
** Leerink Partners ("outperform," PT: $86) says majority of the moving parts in the health care benefits segment are on the right track
** "We continue to see more tailwinds than headwinds" - brokerage
** Morningstar (fair value: $92) says CVS's profit forecast raise sets it apart from peers like CNC, ELV and UNH that cut 2025 guidance after weak results
** TD Cowen ("buy," PT: $95) says they believe second-half guidance still has room for upside
(Reporting by Twesha Dikshit)
((Twesha.Dikshit@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。